Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function
Tao Shen, Ivy Aneas, Noboru Sakabe, Ralf J. Dirschinger, Gang Wang, Scott Smemo, John M. Westlund, Hongqiang Cheng, Nancy Dalton, Yusu Gu, Cornelis J. Boogerd, Chen-leng Cai, Kirk Peterson, Ju Chen, Marcelo A. Nobrega, Sylvia M. Evans
Tao Shen, Ivy Aneas, Noboru Sakabe, Ralf J. Dirschinger, Gang Wang, Scott Smemo, John M. Westlund, Hongqiang Cheng, Nancy Dalton, Yusu Gu, Cornelis J. Boogerd, Chen-leng Cai, Kirk Peterson, Ju Chen, Marcelo A. Nobrega, Sylvia M. Evans
View: Text | PDF
Research Article Cardiology

Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function

  • Text
  • PDF
Abstract

Human mutations in or variants of TBX20 are associated with congenital heart disease, cardiomyopathy, and arrhythmias. To investigate whether cardiac disease in patients with these conditions results from an embryonic or ongoing requirement for Tbx20 in myocardium, we ablated Tbx20 specifically in adult cardiomyocytes in mice. This ablation resulted in the onset of severe cardiomyopathy accompanied by arrhythmias, with death ensuing within 1 to 2 weeks of Tbx20 ablation. Accounting for this dramatic phenotype, we identified molecular signatures that posit Tbx20 as a central integrator of a genetic program that maintains cardiomyocyte function in the adult heart. Expression of a number of genes encoding critical transcription factors, ion channels, and cytoskeletal/myofibrillar proteins was downregulated consequent to loss of Tbx20. Genome-wide ChIP analysis of Tbx20-binding regions in the adult heart revealed that many of these genes were direct downstream targets of Tbx20 and uncovered a previously undescribed DNA-binding site for Tbx20. Bioinformatics and in vivo functional analyses revealed a cohort of transcription factors that, working with Tbx20, integrated multiple environmental signals to maintain ion channel gene expression in the adult heart. Our data provide insight into the mechanisms by which mutations in TBX20 cause adult heart disease in humans.

Authors

Tao Shen, Ivy Aneas, Noboru Sakabe, Ralf J. Dirschinger, Gang Wang, Scott Smemo, John M. Westlund, Hongqiang Cheng, Nancy Dalton, Yusu Gu, Cornelis J. Boogerd, Chen-leng Cai, Kirk Peterson, Ju Chen, Marcelo A. Nobrega, Sylvia M. Evans

×

Figure 1

Cardiomyocyte-specific ablation of Tbx20 in adult mice results in cardiac chamber dilation and lethality.

Options: View larger image (or click on image) Download as PowerPoint
Cardiomyocyte-specific ablation of Tbx20 in adult mice results in cardia...
(A) Tbx20 protein expression in different fractions of the heart (representative result from 3 independent experiments). (B) α-MHC–mER–Cre–mER activity shown by X-gal in R26RlacZ/lacZ hearts after 5 days of tamoxifen treatment. Original magnification, ×10. (C) Time course of Tbx20 expression after initiation of tamoxifen treatment in α-MHC–mER–Cre–mER/Tbx20f/f mice. Western blot (top) and densitometry analysis (bottom); representative results from 4 independent experiments. Data are expressed as mean ± SEM. **P < 0.01. (D) Survival of Tbx20 conditional KO and control mice. Control, n = 25 (Tbx20 flox, n = 15; α-MHC–mER–Cre–mER, n = 10); Tbx20 conditional KO (cKO), n = 26. (E) H&E staining of Tbx20 conditional KO and control hearts 7 days after tamoxifen treatment. Original magnification, ×10. (F) TUNEL staining 5 days after initiation of tamoxifen treatment. Original magnification, ×200. Arrows indicate TUNEL-positive nuclei. LA, left atrium; RA, right atrium; SP, interventricular septum; LV/RV, LV/RV free wall.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts